key: cord-1021075-wz4gyvzq
authors: Luo, Meng-Si; Huang, Guan-Jiang
title: Letter regarding “Association of liver abnormalities with in-hospital mortality in patients with COVID-19”
date: 2021-04-24
journal: J Hepatol
DOI: 10.1016/j.jhep.2021.04.023
sha: 970383cf9db84a776ac5493e9c0e6dccd98c4cca
doc_id: 1021075
cord_uid: wz4gyvzq

nan

Letter regarding "Association of liver abnormalities with in-hospital mortality in patients with COVID-19"

To the Editor:

With great enthusiasm, we read a breakthrough study demonstrating the association of liver abnormalities with in-hospital mortality in patients with COVID-19. 1 Integrating 10 candidate predictor parameters determined by multivariate regression analyses, Ding and colleagues formulated a novel prognostic nomogram to predict the survival of patients with COVID-19.

However, several crucial pitfalls should be taken into account.

In the study of Ding et al., 1 a total of 2,073 patients with COVID-19 were involved. Subsequently, 10 candidate predictor parameters (including age, severe pneumonia, lymphocyte count, PLT, CRP, D-dimer, creatinine, cTnl, AST, and D-Bil) were selected to construct the prognostic model and plot the nomogram. However, is the limited sample size large enough to establish the prediction model which can predict the overall survival probability of patients with COVID-19? As a matter of fact, we are skeptical about the reliability of this nomogram. In the authoritative methodological research published in the journal of BMJ, Riley et al. 2 The result is shown in Fig. 1A , indicating that at least 11,200 patients are required for 14-day survival prediction, corresponding to 1,164.8 deaths and an EPP (events per candidate predictor parameter) of 11.18. In addition, the minimum required sample sizes of 21-day and 28-day survival prediction were also calculated ( Fig. 1B and C) . Therefore, the minimum required sample size to construct the prognostic nomogram should be 11,200 patients, which is much larger than the sample size (2,073 patients) of Ding et al.'s study.

Moreover, though the calibration curve showed good consistency, the ROC (receiver operating characteristic) curve and DCA (decision curve analysis) curves were eagerly warranted. 4, 5 The ROC curve can evaluate the discriminative ability of the nomogram, while the DCA curve can evaluate the clinical usefulness of the nomogram. Furthermore, Ding et al.'s nomogram would be more valuable if they applied the disease-specific survival to establish the prognostic nomogram. 6 After all, the overall survival may be impacted by other factors except for COVID-19.

We appreciate Ding et al. for their vital thoughts on the association between liver abnormalities and COVID-19, which has paved a novel way to predict the overall survival probability of patients with COVID-19. However, the minimum required sample size to construct the prognostic nomogram in Ding et al.'s study should be 11,200 patients. The discriminative ability and the clinical usefulness of the nomogram were definitely necessary. Consequently, these above issues may strongly impact the reliability and applicability of Ding et al.'s nomogram. 

Association of liver abnormalities with in-hospital mortality in patients with COVID-19

Calculating the sample size required for developing a clinical prediction model

Minimum sample size for developing a multivariable prediction model: PART II-binary and time-to-event outcomes

Use and misuse of the receiver operating characteristic curve in risk prediction

Decision curve analysis: a novel method for evaluating prediction models

Overall survival vs disease-specific survival

We are grateful to Dr. Hui-Zi Li for his professional support. We are grateful to Dr. Li-Lan Lei (my English teacher), Dr. Ling-Jun Wang, and Dr. Chen-Yang Huang for proofreading and editing.

Supplementary data to this article can be found online at https:// doi.org/10.1016/j.jhep.2021.04.023.